Louisiana State Employees Retirement System Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH

Louisiana State Employees Retirement System bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,100 shares of the medical equipment provider’s stock, valued at approximately $913,000.

A number of other large investors also recently modified their holdings of ZBH. Inceptionr LLC acquired a new position in Zimmer Biomet during the third quarter worth $1,217,000. PNC Financial Services Group Inc. boosted its stake in shares of Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares in the last quarter. Wilsey Asset Management Inc. bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $32,439,000. Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock worth $223,503,000 after purchasing an additional 39,146 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after purchasing an additional 24,748 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.0%

Shares of NYSE:ZBH opened at $87.50 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a market cap of $16.93 billion, a P/E ratio of 22.73, a P/E/G ratio of 2.58 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company’s 50-day moving average price is $86.09 and its two-hundred day moving average price is $89.79.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is 24.94%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ZBH shares. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus reduced their target price on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Finally, Barclays decreased their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.